# Pizarra — PT-pseudo_20ba3f0f6ca0 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_20ba3f0f6ca0
Task: 1

Encounter: Urology - outpatient on 01 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 4.8 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.086 ng/mL²
  - PSA velocity: 0.35 ng/mL/yr
  - Prior PSA: 3.8 ng/mL
  - Prostate volume: 56.0 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7257912 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 4.8 ng/mL. PI-RADS 4. PSAD 0.09. Prostate volume 56 mL. DRE nodus. csPCa 0.73.

Vitals: weight 76 kg, height 188 cm, BMI 21.5, BP 131/58 mmHg, HR 71 bpm. Smoking: Ex-smoker (11 pack-yr, quit 2023).

Chief complaint: A recent elevation of prostate-specific antigen to 4.8 ng/mL, coupled with a multiparametric MRI conducted at Jeroen Bosch Ziekenhuis, prompted this consultation.

History: A semi-retired musician with a smoking history of 11 pack-years (cessation in 2023) seeks evaluation for a progressively rising PSA and recent imaging results. He reports zero lower urinary tract symptoms, denies haematuria, bone pain, or unexplained weight loss, and maintains a daily 45-minute walking routine alongside a modest alcohol intake of roughly 2 units weekly. Following a recent move, he now shares a residence with his sister, who acts as his next of kin, while his marital status remains married though he currently lives apart from his spouse. Past medical encounters include a routine audiology assessment for mild hearing loss and a dermatology visit for actinic keratosis surveillance; otherwise, his health history is clear, with no comorbidities and no active medications. His prior biopsy bucket remains None. He relies on written summaries during consultations due to mild hearing impairment.

Physical examination: DRE — texture: firm, mobility: unrestricted, asymmetry: Nodus palpable in the right mid-gland peripheral zone. Abdominal and cardiovascular assessments show no abnormalities, recording a blood pressure of 131/58 mmHg and a regular heart rate of 71 bpm. Peripheral lymphadenopathy and hepatosplenomegaly are absent.

Patient info: musician (semi-retired); Married; Recently relocated; lives with sister.
Next of kin: Sibling (sister).

Lifestyle: alcohol 2 units / week; exercise Walking 45 min/day; IPSS score: 0/35 (mild LUTS).

Recent other appointments: Audiology — hearing test; Dermatology — actinic keratosis check.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.77 +/- 0.17   (95% CI 0.37-0.99)

Where the uncertainty comes from:
  - aleatoric  dA = 0.15  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.07  (few labelled cases resemble this one)
  - 4.9 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'supports': A +/- dA does not cross 0.5, but A +/- 1.96*dA does. There is a direction, not a conclusion. Measured accuracy in this tier: 0.67. Treat it as a weighted vote, not as a decision.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=0.0, psa=4.8, age=65.0, psad=0.086, dre_ord=1.0, vol=56.0, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender only used the structured panel. It could not weigh the patient's PSA velocity (0.35 ng/mL/yr) or the specific findings from the mpMRI report (PI-RADS 4) beyond the score itself, nor the full context of the PSA history trend. It also missed the specific details from the laboratory panel and previous notes that might modify the risk profile.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests biopsy (0.77), but the PI-RADS score is 4 (high risk), yet the prior biopsy status is 'None'. This combination, especially with a rising PSA (from 3.8 to 4.8), suggests a need for action, but the prior does not account for the specific clinical context or the uncertainty inherent in the PI-RADS 4 score. The wide error bar ($\pm 0.17$) indicates significant disagreement among the training set, suggesting the model is highly uncertain about this specific profile.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details specific suspicious lesions or features, it would refine the PI-RADS 4 assessment.
  <document> PSA history (trend) -> If the trend shows a steeper rise or a more concerning velocity, it would increase the urgency for biopsy.
  <document> previous GP / urology consultation notes -> These notes might contain prior discussions or specific clinical context not captured in the structured panel.
  <document> laboratory results (full panel) -> This could reveal other markers (e.g., PSA density context) that influence risk stratification.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number.
  
  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_20ba3f0f6ca0", "radiology_report": "Study: Multiparametric MRI Prostate | Facility: Jeroen Bosch Ziekenhuis ('s-Hertogenbosch) | Date: 28 Dec 2024\nClinical Indication: Evaluation of a 65-year-old male with a PSA value of 4.8 ng/mL and a prior PI-RADS 4 on screening.\nFINDINGS: The prostate gland measures 56.0 mL in volume. T2-weighted sequences reveal a focal area of marked hypointensity within the right peripheral zone at the mid-gland level, spanning approximately 12 x 9 x 8 mm. Restricted diffusion is noted on DWI with corresponding low signal on the ADC map. Dynamic contrast-enhanced sequences demonstrate early, focal enhancement relative to the surrounding parenchyma. The seminal vesicles appear unremarkable. No extracapsular extension or suspicious lymphadenopathy is identified.\nIMPRESSION: PI-RADS 4 lesion in the right peripheral zone mid-gland, consistent with a high probability of clinically significant prostate cancer. Prostate volume 56.0 yields a PSA density of 0.086 ng/mL/mL. csPCa predicted probability 0.7257912."}
  
  **psa_trend**
  {"case_id": "PT-pseudo_20ba3f0f6ca0", "psa_trend": [{"date": "May 2023", "val": 4.1}, {"date": "Oct 2023", "val": 4.5}, {"date": "Mar 2024", "val": 4.5}, {"date": "Aug 2024", "val": 2.9}, {"date": "Jan 2025", "val": 4.8}]}
  
  **previous_notes**
  {"case_id": "PT-pseudo_20ba3f0f6ca0", "previous_notes": [{"date": "06 May 2024", "author": "Dr. C. Peters (GP)", "text": "A routine assessment highlighted a progressive increase in prostate-specific antigen levels. The most recent draw, conducted in March 2024, recorded a value of 3.6 ng/mL, continuing a slow upward trajectory observed over prior years. Given this pattern alongside his age, a urology consultation and multiparametric MRI were coordinated. Urinary function remains completely unaffected, and he continues his weekly music rehearsals without interruption."}, {"date": "12 Jan 2023", "author": "Dr. C. Peters (GP)", "text": "Initial screening identified a prostate-specific antigen concentration of 3.3 ng/mL, marking a slight elevation for his demographic. Lower urinary tract symptoms and systemic complaints were absent. A subsequent test was planned for later in the calendar year to track progression. He maintained his existing lifestyle and exercise regimen, with no urgent clinical actions required at that time."}]}
  
  **laboratory_results**
  {"case_id": "PT-pseudo_20ba3f0f6ca0", "laboratory_results": [{"name": "PSA", "val": "4.8 ng/mL", "date": "23 Nov 2024", "flag": "H"}, {"name": "Free PSA", "val": "1.25 ng/mL", "date": "23 Nov 2024", "flag": ""}, {"name": "%Free PSA", "val": "26%", "date": "23 Nov 2024", "flag": ""}, {"name": "Haemoglobin", "val": "13.7 g/dL", "date": "23 Nov 2024", "flag": ""}, {"name": "WBC", "val": "4.5 x10^9/L", "date": "23 Nov 2024", "flag": ""}, {"name": "Platelets", "val": "272 x10^9/L", "date": "23 Nov 2024", "flag": ""}, {"name": "Creatinine", "val": "105 umol/L", "date": "23 Nov 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "23 Nov 2024", "flag": ""}, {"name": "Testosterone", "val": "15.2 nmol/L", "date": "23 Nov 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "63 U/L", "date": "23 Nov 2024", "flag": ""}, {"name": "LDH", "val": "123 U/L", "date": "23 Nov 2024", "flag": ""}]}

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - PI-RADS 4 lesion in the right peripheral zone mid-gland, consistent with a high probability of clinically significant prostate cancer.
  - PSA velocity of 0.35 ng/mL/yr, with a recent rise from 3.8 ng/mL to 4.8 ng/mL.
  - csPCa predicted probability of 0.7257912.
  
  AGAINST sampling this patient now:
  - Free PSA of 1.25 ng/mL (26%).

WHERE THIS LEANS
  The retrieved evidence strongly supports the need for further investigation due to the high-risk MRI finding (PI-RADS 4) and the rising PSA trend, which aligns with the statistical prior's suggestion to biopsy. The finding of a 26% Free PSA is a factor that might temper the urgency, but the high PI-RADS score and PSA velocity push towards intervention.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended due to the convergence of high-risk imaging and rising PSA. The PI-RADS 4 lesion in the right peripheral zone mid-gland, coupled with a PSA velocity of 0.35 ng/mL/yr and a recent PSA rise from 3.8 to 4.8 ng/mL, strongly justifies sampling. While the 26% Free PSA is a tempering factor, the high PI-RADS score and PSA trend are decisive factors pushing towards intervention.

Variables that carried weight: age=noted, dre=noted, psa=decisive, vol=noted, psad=noted, pirads=decisive
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
